ArticleBlood2026
Oxidized PDI promotes thrombus formation in oxidative stress.
Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Luminespib and AZ5104 are effective antithrombotic drugs via targeting the platelet Ero1α-PDI pathway.Science advances · 2026Article
- Article
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
Abstract
abstractProtein disulfide isomerase (PDI) functions in thrombus formation in vivo and represents a viable target for antithrombotic therapy. PDI is a redox sensor that can either reduce or oxidize substrates depending on the redox environment. However, whether PDI functions primarily as a reductase or an oxidase in the context of thrombus formation remains unknown. Here, we used pharmacological and genetic approaches along with PDI mutants to determine how the PDI redox state affects thrombus formation. LOC14, which inhibits PDI reductase activity and induces PDI oxidation, promoted thrombus formation in arteries exposed to ferric chloride and enhanced laser injury-induced platelet accumulation and fibrin formation in cremaster arterioles. Blocking antibodies targeting PDI reversed the prothrombotic effect of LOC14. Evaluation of sulfenylation-mediated PDI oxidation using the C53A, C56A, R120D, and T101A PDI mutants showed that the sulfenylation mechanism of PDI resembles that of hydrogen peroxide (H2O2) reduction by peroxiredoxins. These studies identified PDI mutants that failed to undergo H2O2-mediated oxidation, but showed normal reductase activity. When tested in vivo, either wild-type PDI or the R120D mutant fully restored normal thrombus formation following morpholino-induced knockdown of PDI or in mice with platelet-specific knockout of PDI. In contrast, the sulfenylation-impaired R120D mutant PDI was unable to fully restore thrombus formation in the setting of oxidative stress induced in mice by genetic deletion of glutathione peroxidase 3 or by infusion of oxidized low-density lipoproteins. These studies show that PDI-catalyzed oxidation drives thrombosis and demonstrates a mechanism of peroxide-mediated oxidation of PDI that contributes to the prothrombotic response of oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.